Assessment of pharmacokinetics, safety, and tolerability following twice‐daily administration of molnupiravir for 10 days in healthy participants

• Κύριοι συγγραφείς: Marian Iwamoto (Συγγραφέας), Kelly E. Duncan (Συγγραφέας), Prachi K. Wickremasingha (Συγγραφέας), Tian Zhao (Συγγραφέας), Maria V. Liberti (Συγγραφέας), Lieselotte Lemoine (Συγγραφέας), Tatjana Decaesteker (Συγγραφέας), Sylvie Rottey (Συγγραφέας), Brian M. Maas (Συγγραφέας), Gillian Gillespie (Συγγραφέας), S. Aubrey Stoch (Συγγραφέας)
• Μορφή: Βιβλίο
• Έκδοση: Wiley, 2023-10-01T00:00:00Z.
• Θέματα: article
• Διαθέσιμο Online: Connect to this object online.

Abstract Molnupiravir is an orally administered, small‐molecule ribonucleoside prodrug of β‐D‐N4‐hydroxycytidine (NHC) that has demonstrated potent, broad‐spectrum preclinical activity against RNA viruses and has a high barrier to the development of resistance. A double‐blind, placebo‐controlled, ph...